ReviewFrontiers in oncology2020
Denosumab in Giant Cell Tumor of Bone: Current Status and Pitfalls.
Review in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Roles of TNF Signaling Pathways in Metabolism of Bone Tumors.Frontiers in pharmacology · 2022Pooled it
- Dual-target neoadjuvant therapy with denosumab and sunitinib for giant cell tumor of bone: a sarcoma center experience.Journal of bone oncology · 2026Article
- Giant Cell Tumor of the Sacrum: A Narrative Review of Management Challenges and Modalities.Healthcare (Basel, Switzerland) · 2026Review
- Functional Outcome of Curettage and Chemical Cauterization with Bone Grafting and Fixation with Neo-Adjuvant Denosumab Therapy in a Case of Giant Cell Tumor of Navicular Bone of a Young Adult - A Case Report.Journal of orthopaedic case reports · 2026Article
- Giant Cell Tumor of Bone: Biology, Pathophysiology, and Histopathology in the Era of H3F3A.Biomedicines · 2026Review
- Surgical approaches for the treatment of giant cell tumor of bone in Tunisian patients: association with recurrence.The Libyan journal of medicine · 2025Article
- Recurrent Giant Cell Tumor of the Carpal Bones in an Adult Male Managed by En-bloc Excision, Extended Curettage, Bone Grafting, and all-Kirschner Wire Fixation: A Rare Case Report and Literature Review.Journal of orthopaedic case reports · 2025Article
- Malignant and metastatic giant cell tumors of bone; clinical course of primary or secondary malignant and pulmonary metastatic variants.Journal of bone oncology · 2025Article
- Article
- Clinical Audit of Denosumab Biosimilar for Aggressive GCT of Bone: A Tertiary Care Center Retrospective Analysis.South Asian journal of cancer · 2025Article
- Skip Lesion in Distal Femur with Recurrent Giant Cell Tumor of the Proximal Femur: A Very Rare Case Managed with Excision, Megaprosthesis Reconstruction, and Bone Cement Curettage.Journal of orthopaedic case reports · 2025Article
- Functional Outcomes of Surgical Treatment for Giant Cell Tumors around the Knee.Journal of orthopaedic case reports · 2025Article
- Article
- Surgical and radiological outcomes of giant cell tumor of the bone: prognostic value of Campanacci grading and selective use of denosumab.Journal of orthopaedics and traumatology : official journal of the Italian Society of Orthopaedics and Traumatology · 2025Article
- Giant cell tumor of the bone with fatal pulmonary metastasis: A case report.SAGE open medical case reports · 2025Article
- A Review on Bone Tumor Management: Cutting-Edge Strategies in Bone Grafting, Bone Graft Substitute, and Growth Factors for Defect Reconstruction.Orthopedic research and reviews · 2025Review
- Establishment and characterization of NCC-GCTB10-C1: a novel cell line derived from a patient with recurrent giant cell tumor of bone.Human cell · 2024Article
- Cellular crosstalk in the bone marrow niche.Journal of translational medicine · 2024Review
- A Short Course of Preoperative Denosumab Injection Followed by Surgery in High-Risk Giant Cell Tumors of the Extremities: A Retrospective Study.Indian journal of surgical oncology · 2024Article
- How Arterial Embolization Is Transforming Treatment of Oncologic and Degenerative Musculoskeletal Disease.Current oncology (Toronto, Ont.) · 2024Review
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Denosumab is a monoclonal antibody against RANK ligand for treatment of giant cell tumor of bone (GCTB). Clinical trials and case series have demonstrated that denosumab is relevant to beneficial tumor response and surgical down-staging in patients of GCTB. However, these trials or case series have limitations with a short follow-up. Recent increasing studies revealed that denosumab probably increased the local recurrence risk in patients treated with curettage. This may be caused by the thicken bone margin of tumor that trapped tumor cells from curettage. The direct bone formation by tumor cells in the margin after denosumab treatment also contributed to the local recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.